Although GSK2879552 is currently under clinical development to investigate the anti-tumor potential of KDM1A inhibition in SCLC, this targeted mechanistic approach in combination with its role as a predictive biomarker makes the inhibition of KDM1A an exciting therapeutic drug target for SCLC treatment [144]. Here, KDM1A is linked to neoplasm.